Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Hematologic Malignancies
•
Radiation Oncology
•
Medical Oncology
•
Lymphoma
•
Hematology
What is the role of radiation consolidation after chemotherapy for residual splenic involvement in follicular lymphoma?
Answer from: Radiation Oncologist at Academic Institution
Recommend 3000 cGy in 15 fractions
Sign in or Register to read more
808
Related Questions
Does tolerance of prior BTKi therapy or specific agent used (e.g., ibrutinib, acalabrutinib) influence your starting dose of pirtobrutinib?
What post-protocol therapies did patients on the BRUIN trial in CLL receive, and how did these therapies impact outcomes?
How does pirtobrutinib compare to other available therapies for relapsed/refractory CLL after BTK inhibitor treatment, particularly in terms of efficacy and tolerability?
How do CLL patients with downstream treatment-resistant mutations such as PLCG2 respond to pirtobrutinib?
For a patient with ENKTL nasal type (nose/sinus involvement) who has hepatic toxicity with pegasparaginase but a CR after 2 cycles of chemotherapy with a plan for "sandwich" radiotherapy - what, if any, chemotherapy would you resume after completion of radiation?
Is there any evidence for amyloid/amyloidosis causing a spurious/false PSA reading?
How would you manage a healthy 31 younger patient with nodular lymphocyte predominant Hodgkin lymphoma with severe hemolytic anemia but no other symptoms that responded to steroids?
How would you approach fertility preservation in a young patient with DLBCL requiring R-CHOP?
How would you manage a stage IE Burkitt lymphoma with stable disease after three cycle of DA-R-EPOCH?
Given the data from SWOG 1826 suggesting that Nivo-AVD is likely the preferred regimen for advanced Hodgkin lymphoma patients, are there scenarios where alternative regimens may still be preferred?